The causes of the broad spectrum of severity in COVID-19 are unknown. A protecting impact by humoral immunity from earlier infections by viruses of the SARS-CoV-2 household may clarify a light type of this illness. This examine aimed to deal with whether or not the presence of antibodies in opposition to human seasonal coronaviruses (HCoVs) may forestall extreme manifestations of COVID-19.
A cross-sectional examine was carried out in 165 members. The presence of pre-existent antibodies in opposition to the seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63 have been detected. From all the seasonal HCoVs studied, it was solely discovered that being seropositive to HCoV-229E introduced an affiliation (p = 0.012) with creating delicate medical signs of COVID-19 or being asymptomatic.
Multinomial regression evaluation confirmed that being seropositive to HCoV-229E is related to delicate or reasonable medical signs for COVID-19. Statistical evaluation additionally confirmed that being feminine is related to being asymptomatic for SARS-CoV-2 an infection or creating delicate COVID-19.
A subgroup evaluation taking solely seropositive to HCoV-229E revealed that females usually tend to develop asymptomatic SARS-CoV-2 an infection (OR = 27.242, 95% CI 2.092-354.706, p = 0.012). Our outcomes recommend that earlier infections by HCoV-229E may forestall extra critical medical manifestations of COVID-19, however these should not the one variables that affect this occasion.
The comparative efficacy and security of anti-CD20 monoclonal antibodies for relapsing-remitting a number of sclerosis: A community meta-analysis
With the latest profitable concentrating on of B lymphocytes in sufferers with a number of sclerosis (MS), therapy with anti-CD20 monoclonal antibodies (mAbs) might characterize a promising managemental strategy, significantly for these with relapsing/remitting MS (RRMS).
A community meta-analysis was carried out based mostly on a complete search in Embase, PubMed, and the Cochrane Library to evaluate the comparative efficacy and security of at present obtainable anti-CD20 monoclonal antibodies (mAbs), together with rituximab, ocrelizumab, and ofatumumab, versus a standard comparator (interferon beta-1a [INFβ-1a]) in RRMS sufferers recruited in randomized medical trials (RCTs).
In a frequentist community meta-analytical mannequin, annualized relapse charges (ARRs) and security outcomes have been expressed as threat ratios (RRs), whereas relapse-free occasions have been expressed as odds ratios (ORs). Remedy rating was carried out utilizing P-scores. The knowledge of proof was appraised utilizing the GRADE strategy.
5 publications reported the outcomes of seven RCTs (3938 sufferers, 67.09% females). In comparison with INFβ-1a, ocrelizumab lowered the chance of ARR (RR = 0.56, 95% CI, 0.50-0.64), critical adversarial occasions (RR = 0.17, 95% CI, 0.09-0.30), and therapy discontinuation as a consequence of adversarial occasions (SAEs, RR = 0.60, 95% CI, 0.39-0.93), and it was related to larger odds of no relapses (OR = 2.47, 95% CI, 2.00-3.05).
Ocrelizumab ranked finest amongst all different remedies by way of lowering ARR and SAEs. The standard of proof was low for ocrelizumab, low to reasonable for rituximab, and excessive for ofatumumab. Additional large-sized, well-designed RCTs are wanted to corroborate the efficacy and security of ocrelizumab and different anti-CD20 mAbs in RRMS.
Fc Receptor Variants and Illness: A Essential Issue to Contemplate within the Antibody Therapeutics in Clinic
The fragment crystallizable (Fc) area of antibodies is answerable for their protecting perform and long-lasting serum half-life by way of Fc-mediated effector perform, transcytosis, and recycling by its interplay with Fc receptors (FcRs) expressed on varied immune leukocytes, epithelial, and endothelial cells. Due to this fact, the Fc-FcRs interplay is a management level of each endogenous and therapeutic antibody perform.
There are a variety of reported genetic variants of FcRs, which embrace polymorphisms in (i) extracellular area of FcRs, which change their affinities to Fc area of antibodies; (ii) each cytoplasmic and intracellular area, which alters the extent of sign transduction; and (iii) the promoter area of the FcRs gene, which impacts the expression degree of FcRs, thus being related to the pathogenesis of illness indications.
On this assessment, we firstly describe the correlation between the genetic variants of FcRs and immunological problems by particular person variations within the extent of FcRs-mediated laws. Secondly, we focus on the affect of the genetic variants of FcRs on the susceptibility to infectious ailments or most cancers within the perspective of FcRs-induced effector capabilities. General, we concluded that the genetic variants of FcRs are one of many key components within the design of antibody therapeutics as a consequence of their number of medical outcomes amongst people.

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies Could Ameliorate COVID-19 Issues in APECED Sufferers
Sufferers with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is brought on by loss-of-function mutations within the autoimmune regulator (AIRE) gene, uniformly carry neutralizing autoantibodies directed in opposition to type-I interferons (IFNs) and lots of develop autoimmune pneumonitis, each of which place them at excessive threat for life-threatening COVID-19 pneumonia.
Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that focus on the SARS-CoV-2 spike protein and block entry of SARS-CoV-2 in host cells. Using bamlanivimab and etesevimab early throughout an infection was related to lowered COVID-19-associated hospitalization and dying in sufferers at excessive threat for progressing to extreme illness, which led the US Meals and Drug Administration to subject an emergency use authorization for his or her administration in non-hypoxemic, non-hospitalized high-risk sufferers.
Nevertheless, the protection and efficacy of those mAbs has not been evaluated in APECED sufferers. We enrolled two siblings with APECED on an IRB-approved protocol and admitted them prophylactically on the NIH Medical Heart for analysis of mild-to-moderate COVID-19. We assessed the protection and medical results of early therapy with bamlanivimab and etesevimab.
The administration of bamlanivimab and etesevimab was effectively tolerated and was related to amelioration of COVID-19 signs and prevention of invasive ventilatory help, admission to the intensive care, and dying in each sufferers with out affecting the manufacturing of antibodies to the nucleocapsid protein of SARS-CoV-2.
If given early in the midst of COVID-19 an infection, bamlanivimab and etesevimab could also be useful in APECED and different high-risk sufferers with neutralizing autoantibodies directed in opposition to type-I IFNs.

Case Report: Full Response of Main Large Hepatocellular Carcinoma to Anti-Programmed Demise Ligand-1 Antibody Following Development on Anti-Programmed Demise-1 Antibody
Hepatocellular carcinoma (HCC) is an aggressive liver tumor that happens as a consequence of persistent liver illness, and it has a excessive mortality charge and restricted therapy choices. Immune checkpoint inhibitors have been efficiently launched and utilized in most cancers remedy, amongst which inhibitors of programmed dying ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are generally administered for HCC as mixture remedy, together with mixed anti-angiogenic and immunotherapy mixture remedy.

We report a case of a main large HCC affected person with portal hepatic vein tumor thrombus who had a great response to atezolizumab together with bevacizumab, following development of illness on mixed immunotherapy with pembrolizumab and lenvatinib.
CD54 (pT512) Antibody |
20-abx009840 |
Abbexa |
-
EUR 376.80
-
EUR 560.40
-
EUR 243.60
|
|
|
ICAM1 Antibody / CD54 |
RQ7001 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: CD54, also known as ICAM-1 and Intercellular adhesion molecule-1 (ICAM1) is a ligand for lymphocyte function-associated (LFA) antigens. ICAM-1 is an integral membrane protein, a member of the immunoglobulin superfamily, and a ligand for LFA-1, a beta 2 leukocyte integrin. This protein is the major human rhinovirus receptor. The ICAM1 gene is mapped to human chromosome 19. In humans, lymphocyte adhesion to cells is mediated by the protein heterodimer CD11a/CD18 (Leu-CAMa, LFA-1) and its ligand CD54 (ICAM-1). |
ICAM1 Antibody / CD54 |
RQ7002 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: CD54, also known as ICAM-1 and Intercellular adhesion molecule-1 (ICAM1) is a ligand for lymphocyte function-associated (LFA) antigens. ICAM-1 is an integral membrane protein, a member of the immunoglobulin superfamily, and a ligand for LFA-1, a beta 2 leukocyte integrin. This protein is the major human rhinovirus receptor. The ICAM1 gene is mapped to human chromosome 19. In humans, lymphocyte adhesion to cells is mediated by the protein heterodimer CD11a/CD18 (Leu-CAMa, LFA-1) and its ligand CD54 (ICAM-1). |
ICAM1 Antibody / CD54 |
RQ5121 |
NSJ Bioreagents |
100ul |
EUR 356.15 |
Description: The ICAM1 gene encodes a cell surface glycoprotein which is typically expressed on endothelial cells and cells of the immune system. It binds to integrins of type CD11a / CD18, or CD11b / CD18 and is also exploited by Rhinovirus as a receptor. [RefSeq] |
ICAM1 Antibody / CD54 |
V9194-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V9194-20UG |
NSJ Bioreagents |
20ug |
EUR 153.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V9194SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V9197-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. |
ICAM1 Antibody / CD54 |
V9197-20UG |
NSJ Bioreagents |
20ug |
EUR 153.3 |
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. |
ICAM1 Antibody / CD54 |
V9197SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. |
ICAM1 Antibody / CD54 |
V2604-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production). |
ICAM1 Antibody / CD54 |
V2604-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production). |
ICAM1 Antibody / CD54 |
V2604IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production). |
ICAM1 Antibody / CD54 |
V2604SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production). |
ICAM1 Antibody / CD54 |
V2605-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V2605-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V2605SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V7851-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V7851-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors. |
ICAM1 Antibody / CD54 |
V7851SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors. |
CD54 antibody (biotin) |
61R-1516 |
Fitzgerald |
100 ug |
EUR 379.2 |
Description: Mouse monoclonal CD54 antibody (biotin) |
CD54 Antibody (Biotin) |
abx139537-01mg |
Abbexa |
0.1 mg |
EUR 510 |
|
CD54 Blocking Peptide |
20-abx062764 |
Abbexa |
|
|
|
Anti-Hu CD54 PE |
1P-228-T025 |
ExBio |
25 tests |
EUR 168 |
Anti-Hu CD54 PE |
1P-228-T100 |
ExBio |
100 tests |
EUR 288 |
Anti-Hu CD54 PE |
1P-429-T025 |
ExBio |
25 tests |
EUR 168 |
Anti-Hu CD54 PE |
1P-429-T100 |
ExBio |
100 tests |
EUR 288 |
Anti-Hu CD54 APC |
1A-429-T025 |
ExBio |
25 tests |
EUR 168 |
Anti-Hu CD54 APC |
1A-429-T100 |
ExBio |
100 tests |
EUR 288 |
Anti-Hu CD54 FITC |
1F-429-T025 |
ExBio |
25 tests |
EUR 146.4 |
Anti-Hu CD54 FITC |
1F-429-T100 |
ExBio |
100 tests |
EUR 244.8 |
Anti-Ms CD54 FITC |
1F-625-C100 |
ExBio |
0.1 mg |
EUR 212.4 |
Anti-Hu CD54 PerCP |
PC-429-T025 |
ExBio |
25 tests |
EUR 168 |
Anti-Hu CD54 PerCP |
PC-429-T100 |
ExBio |
100 tests |
EUR 288 |
Anti-Hu CD54 Biotin |
1B-429-C025 |
ExBio |
0.025 mg |
EUR 146.4 |
Anti-Hu CD54 Biotin |
1B-429-C100 |
ExBio |
0.1 mg |
EUR 244.8 |
Anti-Hu CD54 Purified |
11-228-C025 |
ExBio |
0.025 mg |
EUR 118.8 |
Anti-Hu CD54 Purified |
11-228-C100 |
ExBio |
0.1 mg |
EUR 189.6 |
Anti-Hu CD54 Purified |
11-229-C025 |
ExBio |
0.025 mg |
EUR 118.8 |
Anti-Hu CD54 Purified |
11-229-C100 |
ExBio |
0.1 mg |
EUR 189.6 |
Anti-Ms CD54 Purified |
11-625-C025 |
ExBio |
0.025 mg |
EUR 91.2 |
Anti-Ms CD54 Purified |
11-625-C100 |
ExBio |
0.1 mg |
EUR 135.6 |
CD54 (pY512) Blocking Peptide |
20-abx062763 |
Abbexa |
|
|
|
CD54 (ICAM-1) Antibody (PE) |
abx022366-100ug |
Abbexa |
100 ug |
EUR 644.4 |
|
Anti-Hu CD54 Alexa Fluor700 |
A7-429-T025 |
ExBio |
25 tests |
EUR 184.8 |
Anti-Hu CD54 Alexa Fluor700 |
A7-429-T100 |
ExBio |
100 tests |
EUR 322.8 |
CD54 (ICAM-1) Antibody (Biotin) |
abx022368-05mg |
Abbexa |
0.5 mg |
EUR 861.6 |
|
CD54 (ICAM-1) Antibody (Biotin) |
abx021458-02mg |
Abbexa |
0.2 mg |
EUR 886.8 |
|
ICAM-1 / CD54 Recombinant Protein |
11-541 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Inter-Cellular Adhesion Molecule 1 (ICAM-1) is also known as Cluster of Differentiation 54 (CD54), is a member of the immunoglobulin superfamily, and is a cell surface glycoprotein which is typically expressed in low concentrations on endothelial cells and cells of the immune system. The protein encoded by this gene is a type of intercellular adhesion molecule continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for LFA-1 (integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 and then transmigrate into tissues. ICAM-1 has been implicated in subarachnoid hemorrhage (SAH). Levels of ICAM-1 are shown to be significantly elevated in patients with SAH over control subjects in many studies. ICAM-1 expressed by respiratory epithelial cells is also the binding site for rhinovirus, the causative agent of most common colds. |
CD54(ICAM-1) Monoclonal Antibody |
27176-100ul |
SAB |
100ul |
EUR 302.4 |
CD54(ICAM-1) Monoclonal Antibody |
27176-50ul |
SAB |
50ul |
EUR 224.4 |
Monoclonal CD54(ICAM-1) Antibody |
AMM03141G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A Monoclonal antibody against Human CD54(ICAM-1). The antibodies are raised in Mouse. This antibody is applicable in WB |
Monoclonal CD54(ICAM-1) Antibody |
AMM03142G |
Leading Biology |
0.1ml |
EUR 580.8 |
Description: A Monoclonal antibody against Human CD54(ICAM-1). The antibodies are raised in Mouse. This antibody is applicable in WB, ICC |
Monoclonal ICAM-1 / CD54 Antibody |
AMM01772G |
Leading Biology |
0.05mg |
EUR 580.8 |
Description: A Monoclonal antibody against Human ICAM-1 / CD54. The antibodies are raised in Mouse. This antibody is applicable in IHC-P, IP, IHC-Fr, Flo |
Rat ICAM-1/CD54 ELISA Kit |
ERI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Goat ICAM-1/CD54 ELISA Kit |
EGTI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Mouse ICAM-1/CD54 ELISA Kit |
EMI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Human ICAM-1/CD54 ELISA Kit |
EHI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Rabbit ICAM-1/CD54 ELISA Kit |
ERTI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Bovine ICAM-1/CD54 ELISA Kit |
EBI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Canine ICAM-1/CD54 ELISA Kit |
ECI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Porcine ICAM-1/CD54 ELISA Kit |
EPI0332 |
Abclonal |
96Tests |
EUR 625.2 |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC401249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF640R conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC401249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF640R conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC551249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF555 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC551249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF555 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC431249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF543 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC431249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF543 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC471249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF647 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC471249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF647 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC801249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC801249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC811249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680R conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC811249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680R conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC611249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF660R conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC611249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF660R conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCB1249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Biotin conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCB1249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Biotin conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNUM1249-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), 1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCP1249-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), PerCP conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC941249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF594 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC941249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF594 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCAP1249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCAP1249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCA1249-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), APC conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCH1249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCH1249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNUB1249-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Concentration: 0.2mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNUB1249-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Concentration: 0.2mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC041249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405S conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC041249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405S conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC051249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405M conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC051249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405M conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC701249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF770 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC701249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF770 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC881249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF488A conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC881249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF488A conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC681249-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF568 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNC681249-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF568 conjugate, Concentration: 0.1mg/mL |
CD54 / ICAM-1 (F4-31C2) Antibody |
BNCR1249-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), RPE conjugate, Concentration: 0.1mg/mL |
Anserini ICAM-1/CD54 ELISA Kit |
EAI0332 |
Abclonal |
96Tests |
EUR 625.2 |
Anti-Hu CD54 Purified Azide Free |
10-429-C025 |
ExBio |
0.025 mg |
EUR 118.8 |
Anti-Hu CD54 Purified Azide Free |
10-429-C100 |
ExBio |
0.1 mg |
EUR 189.6 |
Anti-Ms CD54 Purified Low Endotoxin |
12-625-C100 |
ExBio |
0.1 mg |
EUR 178.8 |
ICAM-1(CD54) Mouse Monoclonal Antibody |
Ab12144-100 |
GenDepot |
100ul |
EUR 578.4 |
VCAM-1(CD54) Mouse Monoclonal Antibody |
Ab73313-050 |
GenDepot |
50ul |
EUR 562.8 |
VCAM-1(CD54) Mouse Monoclonal Antibody |
Ab73313-100 |
GenDepot |
100ul |
EUR 724.8 |
Recombinant Human ICAM-1/CD54 Protein |
RP00272 |
Abclonal |
5 μg |
EUR 163.2 |
Recombinant Mouse ICAM-1/CD54 Protein |
RP01056 |
Abclonal |
5 μg |
EUR 163.2 |
Recombinant Mouse ICAM-1/CD54 Protein |
RP01065 |
Abclonal |
10 μg |
EUR 231.6 |
Human CellExp? ICAM1 /CD54, human recombinant |
7486-100 |
Biovision |
each |
EUR 861.6 |
Human CellExp? ICAM1 /CD54, human recombinant |
7486-20 |
Biovision |
each |
EUR 320.4 |
Anti-ICAM1/Cd54 Rabbit Monoclonal Antibody |
M00171-1 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal ICAM1/Cd54 Antibody. Validated in IF, WB and tested in Human. |
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx021457-02mg |
Abbexa |
0.2 mg |
EUR 560.4 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx415026-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx415028-25ug |
Abbexa |
25 ug |
EUR 326.4 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx415520-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx415521-05mg |
Abbexa |
0.5 mg |
EUR 994.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx415524-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx412166-01mg |
Abbexa |
0.1 mg |
EUR 844.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx413013-05mg |
Abbexa |
0.5 mg |
EUR 861.6 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx413228-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx413229-05mg |
Abbexa |
0.5 mg |
EUR 994.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx413232-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx413235-20ug |
Abbexa |
20 ug |
EUR 326.4 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
20-abx134369 |
Abbexa |
-
EUR 427.20
-
EUR 678.00
-
EUR 360.00
|
|
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx139530-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx139531-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
abx139532-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody |
20-abx009132 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
ELISA kit for Human sICAM-1 (CD54) |
KET6003-48T |
Abbkine |
48T |
EUR 242.4 |
|
Description: Quantitative sandwich ELISA for measuring Human sICAM-1 (CD54) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human sICAM-1 (CD54) |
KET6003-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 1292.4 |
|
Description: Quantitative sandwich ELISA for measuring Human sICAM-1 (CD54) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human sICAM-1 (CD54) |
KET6003-96T |
Abbkine |
96T |
EUR 346.8 |
|
Description: Quantitative sandwich ELISA for measuring Human sICAM-1 (CD54) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
Guinea Pig ICAM-1/CD54 ELISA Kit |
EGI0332 |
Abclonal |
96Tests |
EUR 625.2 |
CD54 (ICAM1) FITC Monoclonal Antibody (Clone 15.2) |
6961-100 |
Biovision |
each |
EUR 444 |
CD54 (ICAM1) FITC Monoclonal Antibody (Clone 15.2) |
6961-25 |
Biovision |
each |
EUR 235.2 |
CD54 [ICAM-1] non-lytic Recombinant Protein |
90-396 |
ProSci |
100 ug |
EUR 651.3 |
Description: Intercellular Adhesion Molecule-1 (ICAM-1, CD54) binds the leukocyte integrins LFA-1 and Mac1. CD54 expression is weak on leukocytes, epithelial and resting endothelial cells, as well as some other cell types, but expression can be stimulated by IFN-gamma, TNF-alpha, IL-1beta and LPS. Soluble CD54 is found in a biologically active form in serum, probably as a result of proteolytic cleavage from the cell surface, and is elevated in patients with various inflammatory syndromes such as septic shock, LAD, cancer and transplantation. |
CD54 [ICAM-1] non-lytic Recombinant Protein |
90-397 |
ProSci |
50 ug |
EUR 468.6 |
Description: Intercellular Adhesion Molecule-1 (ICAM-1, CD54) binds the leukocyte integrins LFA-1 and Mac1. CD54 expression is weak on leukocytes, epithelial and resting endothelial cells, as well as some other cell types, but expression can be stimulated by IFN-gamma, TNF-alpha, IL-1beta and LPS. Soluble CD54 is found in a biologically active form in serum, probably as a result of proteolytic cleavage from the cell surface, and is elevated in patients with various inflammatory syndromes such as septic shock, LAD, cancer and transplantation. |
Rabbit Anti Human Cd54 Polyclonal Antibody,Biotin |
CPBT-65043RH |
Creative Diagnostics |
50 µg |
EUR 1057.2 |
Intercellular Adhesion Molecule 1 (CD54) Antibody (PE) |
abx134368-100Assays |
Abbexa |
100 Assays |
EUR 594 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (PE) |
abx134368-50Assays |
Abbexa |
50 Assays |
EUR 477.6 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (PE) |
abx139533-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (PE) |
abx139535-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (RPE) |
abx413233-100tests |
Abbexa |
100 tests |
EUR 710.4 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (RPE) |
abx413234-25tests |
Abbexa |
25 tests |
EUR 376.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (APC) |
abx139536-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC) |
abx415027-100tests |
Abbexa |
100 tests |
EUR 610.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC) |
abx415522-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC) |
abx415523-05mg |
Abbexa |
0.5 mg |
EUR 861.6 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC) |
abx413230-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC) |
abx413231-25ug |
Abbexa |
25 ug |
EUR 326.4 |
|
Human Intercellular Adhesion Molecule 1 (CD54) Protein |
abx670234-50ug |
Abbexa |
50 ug |
EUR 678 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (PerCP) |
abx139534-100tests |
Abbexa |
100 tests |
EUR 577.2 |
|
Intercellular Adhesion Molecule 1 (CD54) Antibody (Biotin) |
abx412167-50ug |
Abbexa |
50 ug |
EUR 861.6 |
|
This case demonstrates for the primary time that an HCC affected person who’s proof against anti-PD-1 antibody immunotherapy can profit from anti-PD-L1 antibody immunotherapy, offering a probably promising technique for the therapy of HCC.